1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Denali Therapeutics Inc.

Denali Therapeutics Inc.

DNLI
Denali Therapeutics Inc.US flagNASDAQ Global Select
23.83
USD
+0.93
- -
3.78BMarket Cap
Denali Therapeutics Inc.
DNLI
(NASDAQ Global Select)

Recent

price

23.83

P/E

ratio

- -

div

yld

- -

ROIC.AI

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
1.39
0.28
3.08
0.4
0.86
2.41
- -
- -
- -
Revenue per Share
-5.58
-13.49
-5.89
-0.39
-2.07
0.65
-2.39
-2.6
-1.06
-2.57
-2.97
-2.88
Basic EPS, GAAP
-6.03
-12.15
-5.31
0.5
-1.77
3.79
-1.81
-2.09
-2.7
-2.21
-2.44
-2.38
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-5.55
-16.06
-12.73
-2.45
-4.44
-3.24
-5.29
-7.72
-8.11
-9.35
-11.87
-12.34
Book Value per Share
-5.2
-14.65
31.13
5.9
4.13
10.56
7.92
8.3
7.5
7.48
5.87
5.04
Tangible Book Value per Share
3
6
15
93
96
109
122
126
137
164
173
176
Basic Weighted Avg Shares
- -
- -
- -
129
27
336
49
108
331
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
-35.9
-799.1
18.69
-607.78
-314.16
-59.51
- -
- -
- -
Operating Margin (%)
- -
1
3
7
8
9
9
10
17
9
15
15
Depreciation Expense
-17
-87
-88
-36
-198
71
-291
-326
-145
-423
-513
-508
Net Income, GAAP
- -
- -
- -
- -
- -
1.14
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
-28.06
-740.74
21.19
-597.15
-300.56
-43.94
- -
- -
- -
Profit Margin (%)
30
173
395
448
385
1,424
519
1,008
986
762
802
913
Working Capital
- -
- -
- -
- -
69
64
59
53
45
37
27
25
LT Debt
-16
-94
466
547
395
1,151
962
1,042
1,031
1,230
1,014
926
Total Equity
- -
- -
- -
- -
- -
7.35
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
9
10
10
LT Borrowings
- -
- -
- -
LT Finance Leases
35
27
25
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
147
156
159
Market Capitalization
2,487
2,850
3,389

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
883
901
1,023
Cash, Cash Equivalents & STI
848
868
988
Accounts Receivable, Net
- -
2
- -
Inventories
- -
- -
- -
Total Current Liabilities
90
98
110
Payables & Accruals
40
36
76
ST Debt
9
10
10
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.11%
-1.48%
-17.56%
Free Cash Flow
-71.09%
-15.69%
16.09%
Net Income, GAAP
32.89%
-67.88%
21.23%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.68
-0.59
-0.63
-0.67
-2.57
2025
-0.78
-0.72
-0.74
-0.73
-2.97
2026
-0.69
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
OKYO Pharma Limited (OKYO.L)
Lifecome Biochemistry Co.,Ltd. (002868.SZ)
Epizyme, Inc. (EPZM)
Purple Biotech Ltd. (PPBT)
LabTurbo Biotech Corporation (7725.TWO)
Hepion Pharmaceuticals, Inc. (HEPA)
Business
Denali Therapeutics Inc. (NASDAQ: DNLI) develops therapies for neurodegenerative and lysosomal storage diseases. The company focuses on programs targeting Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and mucopolysaccharidosis type IIIA (MPS IIIA), including DNL343 for ALS and frontotemporal dementia, DNL788 for ALS and Parkinson's, tividenofusp alfa for MPS IIIA, and buntanetap for Alzheimer's; it also advances discovery efforts in other rare diseases. Founded in 2015 and headquartered in South San Francisco, California, Denali operates primarily in the United States with a pipeline built on its proprietary Engineered Antibody Transport (ATLAS) and Enzyme Transport Vehicle (ETV) technologies for crossing the blood-brain barrier. Denali Therapeutics serves the biopharmaceutical industry, targeting patients with neurodegenerative disorders through clinical-stage assets and research collaborations. Its geographic operations center in the U.S., with global partnerships extending research impact. The company maintains subsidiaries like Denali Medtech Inc. for manufacturing support.

Company News

APIChatGPT

  • zacks.com

    Will Recent Setbacks Impact Growth Prospects of DNLI Stock?

  • globenewswire.com

    Denali Therapeutics to Give Opening Plenary Address at Alzheimer's Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier

  • zacks.com

    DNLI Stock Surges 59.4% Year to Date: Is There More Room for Growth?

  • zacks.com

    Denali to Sell Priority Review Voucher for $195M Cash Boost

  • globenewswire.com

    Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million

  • seekingalpha.com

    Denali Therapeutics Inc. (DNLI) Presents at Jefferies Global Healthcare Conference 2026 Transcript

  • seekingalpha.com

    Denali Therapeutics: 'Strong Buy' On AVLAYAH Approval And End Of 2026 FTD-GRN Data

  • zacks.com

    Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails

  • fool.com

    Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval

  • marketbeat.com

    Denali Therapeutics Says AVLAYAH Launch Ahead of Expectations After Hunter Syndrome Approval

  • seekingalpha.com

    Denali Therapeutics Inc. (DNLI) Presents at Bank of America Global Healthcare Conference 2026 Transcript

  • zacks.com

    DNLI Q1 Loss Narrower Than Expected, Avlayah Approval Boosts Prospects

  • globenewswire.com

    Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights

  • fool.com

    Privium Fund Opens $5.07 Million Denali Stake Ahead of FDA Drug Approval

  • seekingalpha.com

    Denali: The First Commercial Validation Of The Blood-Brain Barrier Platform

  • zacks.com

    DNLI Gains 25.4% Year to Date: Should You Buy, Sell or Hold the Stock?

  • zacks.com

    Denali Stock Falls as Partner Takeda Ends Collaboration Deal

  • benzinga.com

    Takeda Exits Dementia Drug Partnership With Denali Therapeutics - Here's Why

  • defenseworld.net

    Capricorn Fund Managers Ltd Acquires New Position in Denali Therapeutics Inc. $DNLI

  • defenseworld.net

    SG Americas Securities LLC Increases Stock Position in Denali Therapeutics Inc. $DNLI